五鼎1733.TW Overview

TW Stock
(No presentation for 1733)
OverviewAI AnalysisFinancialsStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

五鼎(1733)AI Insights

五鼎(1733)Overall Performance

五鼎(1733)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

五鼎(1733) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check 1733's Trend

五鼎(1733)Key Information

五鼎(1733)Profile

Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemoglobin screening systems. It also provides pesticide residues check systems; and care management and tele-health services. The company was founded in 1997 and is headquartered in Hsinchu City, Taiwan.

五鼎(1733)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.63
PE Ratio (TTM)
18.07
Forward PE
36.81
PS Ratio (TTM)
1.51
PB Ratio
1.57
Price-to-FCF
22.23
METRIC
VALUE
vs. INDUSTRY
Gross Margin
27.70%
Net Margin
8.38%
Revenue Growth (YoY)
6.60%
Profit Growth (YoY)
-0.43%
3-Year Revenue Growth
-10.16%
3-Year Profit Growth
-4.72%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.63
PE Ratio (TTM)
18.07
Forward PE
36.81
PS Ratio (TTM)
1.51
PB Ratio
1.57
Price-to-FCF
22.23
Gross Margin
27.70%
Net Margin
8.38%
Revenue Growth (YoY)
6.60%
Profit Growth (YoY)
-0.43%
3-Year Revenue Growth
-10.16%
3-Year Profit Growth
-4.72%
default symbol

1733

五鼎

29.45D

0.34%

(0.00)

  • When is 1733's latest earnings report released?

    The most recent financial report for 五鼎 (1733) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1733's short-term business performance and financial health. For the latest updates on 1733's earnings releases, visit this page regularly.

  • Where does 1733 fall in the P/E River chart?

    According to historical valuation range analysis, 五鼎 (1733)'s current price-to-earnings (P/E) ratio is 16.03, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 1733?

    According to the latest financial report, 五鼎 (1733) reported an Operating Profit of 33.24M with an Operating Margin of 7.57% this period, representing a decline of 30.42% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1733's revenue growth?

    In the latest financial report, 五鼎 (1733) announced revenue of 438.99M, with a Year-Over-Year growth rate of -3.3%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1733 have?

    At the end of the period, 五鼎 (1733) held Total Cash and Cash Equivalents of 567.09M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1733 go with three margins increasing?

    In the latest report, 五鼎 (1733) achieved the “three margins increasing” benchmark, with a gross margin of 30.15%%, operating margin of 7.57%%, and net margin of 11.44%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1733's profit trajectory and future growth potential.

  • Is 1733's EPS continuing to grow?

    According to the past four quarterly reports, 五鼎 (1733)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1733?

    五鼎 (1733)'s Free Cash Flow (FCF) for the period is 2.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 61.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.